Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600D |
Therapy | Belvarafenib + Cobimetinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600D | melanoma | sensitive | Belvarafenib + Cobimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Cotellic (cobimetinib) to treatment with Belvarafenib (HM95573) in a melanoma cell line harboring BRAF V600D resulted in greater inhibition of cell proliferation in culture compared to single agent alone (PMID: 33953400). | 33953400 |
PubMed Id | Reference Title | Details |
---|---|---|
(33953400) | ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. | Full reference... |